Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment trial for children and young people with non-rhabdomyosarcoma soft tissue sarcomas
ISRCTN55318937Phase 3Completed
- Sponsor
- Manchester University NHS Foundation Trust
- Start
- Mar 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, open-label trial of ifosfamide and doxorubicin in non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), synovial sarcoma (SS) and soft tissue sarcoma (STS) (2 arms), sponsored by Manchester University NHS Foundation Trust. Primary endpoint: Survival rates and pattern of treatment failure. Started Mar 2006; status: completed.
02
Drugs
ifosfamidedoxorubicin
03
Conditions
non-rhabdomyosarcoma soft tissue sarcoma (NRSTS)synovial sarcoma (SS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ISRCTN55318937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN55318937.